Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR6 | P46095 | 4/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.36 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3589484 | 0.94 | GPR6 (0.39) | GPR6PRKAA2CHRM4CYP3A4CYP2D6 | |
| SCHEMBL3596127 | 0.93 | GPR6 (0.37) | GPR6NPC1PRKAA2CHRM4CYP3A4 | |
| SCHEMBL3592187 | 0.92 | BCHE (0.38) | GPR6PLA2G4ACHRM4BCHEACHE | |
| SCHEMBL13282444 | 0.89 | GPR6 (0.37) | GPR6PRKAA2CHRM4CYP3A4CYP2D6 | |
| SCHEMBL13254339 | 0.89 | FFAR4 (0.36) | FFAR4PLA2G4ANPC1CYP3A4CYP2D6 | |
| SCHEMBL3589821 | 0.89 | PRKAA2 (0.37) | GPR6PRKAA2CYP3A4BCHEACHE | |
| SCHEMBL3600733 | 0.89 | FFAR4 (0.35) | FFAR4PLA2G4ANPC1CYP3A4CYP2D6 | |
| SCHEMBL3600368 | 0.87 | BCHE (0.38) | GPR6PLA2G4ACHRM4BCHEACHE | |
| SCHEMBL3596047 | 0.86 | SIGMAR1 (0.40) | GPR6PRKAA2CHRM4 | |
| SCHEMBL3599076 | 0.85 | USP14 (0.36) | GPR6CHRM4BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-1930320-A1 | NOVEL FUSED PYRROLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
| EP-1930320-A1 | NOVEL FUSED PYRROLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | NR3C1, NR3C2, NR0B1 | GPR6 154/4885FFAR4 56/4885PLA2G4A 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.